Skip to main content

Table 2 Analytical characteristics on admission

From: Annual evolution of the prescription of drugs with prognostic implications in acute decompensated heart failure with reduced ejection fraction

 

De novo without previous heart disease

De novo with previous heart disease

Non-de novo

p

Total

Urea (mg/dL)*

56.5(37.0/84.8)

66.0(40.5/93.3)

55.0(39.0/91.0)

0.540

57(39/88.5)

Creatinine (mg/dL)#

1.49 ± 1.19

1.61 ± 0.95

1.62 ± 1.14

0.551

1.60 ± 1.12

GFR (ml/min/1.73m2)*

56(35/77.5)

45(32/71)

53(32/76)

0.224

52.5(33/75)

NT ProBNP (pg/mL)*

6238(2800/12,152)

8614(3541.5/18518.5)

7713.5(3460.5/15,470)

0.270

7464(3435/15,425)

Sodium (mEq/L)#

138.9 ± 5.2

138.9 ± 4.5

138.6 ± 4.4

0.778

138.7 ± 4.6

Potassium (mEq/L)#

4.32 ± 0.53

4.39 ± 0.70

4.39 ± 0.59

0.601

4.38 ± 0.60

Hemoglobin (g/dL)#

13.0 ± 3.2

13.5 ± 5.5

12.9 ± 3.1

0.284

13.0 ± 3.7

Hematocrit (%)#

39.3 ± 6.6

38.1 ± 8.2

38.8 ± 6.6

0.439

38.8 ± 6.9

Uric acid (mg/dL)#

8.1 ± 2.7

9.0 ± 6.0

8.3 ± 2.9

0.240

8.4 ± 3.6

Cholesterol-HDL (mg/dL)*

36(30/46)

36(28/45)

35(28/43)

0.412

36(29/44)

Cholesterol-LDL (mg/dL) *

75.5(58/99)

73(54/92)

71(54/95)

0.326

72(54/95)

Triglycerides (mg/dL)*

93(72.5/129.5)

97.5(74/124)

95(72/119.5)

0.670

95.5(73.0/120.3)

TSAT (%)*

17(13/26)

17(12/24)

18(13/24)

0.509

18(13/24)

Ferritin (ng/mL)*

193(109/378)

168(79/358)

163(89/335.5)

0.568

168(87/351)

HbA1c (%)#

6.3 ± 1.2

6.8 ± 5.7

6.3 ± 1.2

0.337

6.4 ± 2.6

CA125 (U/mL)*

90.4(36.9/226.3)

90.0(35.9/181.0)

89.9(47.2/200.5)

0.827

90.0(44.7/199.8)

  1. * median (p25/p75)
  2. # mean ± standard deviation
  3. Abbreviations: CA125: carbohydrate antigen 125; GFR: glomerular filtration rate; HbA1c: glycated hemoglobin; NTproBNP: amino-terminal propeptide of B-type natriuretic peptide; TSAT: transferrin saturation